Drug Sponsors

GlaxoSmithKline honors healthcare nonprofits with $40,000 IMPACT Awards

Friday, November 9, 2012 02:02 PM

GlaxoSmithKline has announced five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

More... »

Boston Scientific to acquire Vessix Vascular

Friday, November 9, 2012 12:28 PM

Boston Scientific, a medical device company based in Natick, Mass., is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, a Laguna Hills, Calif.-based held company developing novel RF balloon catheter and bipolar RF generator technology. 

More... »

Sun Pharma to acquire DUSA Pharmaceuticals

Friday, November 9, 2012 12:06 PM

Sun Pharmaceutical, an international, specialty pharmaceutical company based in India, has agreed to acquire DUSA Pharmaceuticals, a Wilmington, Mass.-based dermatology company focused on photodynamic therapy.

More... »

Bausch + Lomb to acquire Technolas Perfect Vision

Friday, November 9, 2012 11:46 AM

Bausch + Lomb, a global eye health company, has exercised its option to purchase all outstanding and unowned shares of Technolas Perfect Vision (TPV), a ophthalmology laser company based in Germany.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Teva names Oberman as CEO of Teva Americas Generics

Wednesday, November 7, 2012 12:14 PM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has made changes to its executive leadership team.

More... »

Takeda to acquire Envoy Therapeutics

Wednesday, November 7, 2012 11:24 AM

Takeda America Holdings, a subsidiary of Japanese, research-based company Takeda Pharmaceutical, has agreed to acquire Envoy Therapeutics, a privately-held drug discovery company based in Jupiter, Fla. Takeda's corporate venture arm, Takeda Ventures, participated in Envoy's series A financing in October 2009.

More... »

Ambit completes $25M financing for AML drug

Wednesday, November 7, 2012 10:36 AM

Ambit Biosciences, a privately held biopharmaceutical company based in San Diego, has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib, for the treatment of acute myeloid leukemia (AML).

More... »

SAFC to support next-gen NSAID product development

Monday, November 5, 2012 11:16 AM

Sigma-Aldrich’s custom manufacturing and services business unit, SAFC, has signed an agreement with South Korea-based CrystalGenomics, a clinical stage biopharmaceutical company, to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID).

More... »

Ziarco founded with Series A financing

Monday, November 5, 2012 11:01 AM

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

More... »